Victory Capital Management
NRIX icon

Victory Capital Management’s Nurix Therapeutics NRIX Stock Holding History

Victory Capital Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$957K Buy
61,774
+41,254
+201% +$684K ﹤0.01% 1860
2025
Q4 		$389K Buy
20,520
+11,490
+127% +$165K ﹤0.01% 2076
2025
Q3 		$83.4K Sell
9,030
-21,140
-70% -$220K ﹤0.01% 2312
2025
Q2 		$344K Buy
30,170
+510
+2% +$5.51K ﹤0.01% 2130
2025
Q1 		$352K Sell
29,660
-30,552
-51% -$511K ﹤0.01% 2107
2024
Q4 		$1.13M Buy
60,212
+38,672
+180% +$886K ﹤0.01% 1752
2024
Q3 		$484K Buy
+21,540
New +$488K ﹤0.01% 2013
2022
Q4 		– Sell
-11,305
Closed -$147K – 2676
2022
Q3 		$147K Sell
11,305
-1,188
-10% -$18.8K ﹤0.01% 2410
2022
Q2 		$158K Buy
12,493
+305
+3% +$3.46K ﹤0.01% 2394
2022
Q1 		$135K Sell
12,188
-135
-1% -$2.4K ﹤0.01% 2475
2021
Q4 		$357K Sell
12,323
-1,168
-9% -$35.4K ﹤0.01% 2324
2021
Q3 		$404K Buy
13,491
+156
+1% +$4.81K ﹤0.01% 2278
2021
Q2 		$354K Buy
13,335
+655
+5% +$19.2K ﹤0.01% 2357
2021
Q1 		$394K Buy
12,680
+1,851
+17% +$70K ﹤0.01% 2306
2020
Q4 		$356K Sell
10,829
-457
-4% -$15.1K ﹤0.01% 2222
2020
Q3 		$394K Buy
+11,286
New +$284K ﹤0.01% 2046

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Victory Capital Management's NRIX Position: Q1 2026 in Review

Victory Capital Management increased its Nurix Therapeutics (NRIX) stake by 201% in Q1 2026, buying an estimated $684K and bringing the position to 61,774 shares worth $957K. The position accounts for ﹤0.01% of the portfolio, ranked #1860.

Victory Capital Management first reported a position in NRIX in Q3 2020 and has held it in 16 quarters since. The position peaked at $1.13M in Q4 2024. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Victory Capital Management held 61,774 shares of Nurix Therapeutics worth $957K as of Q1 2026.
  • Victory Capital Management bought 41,254 Nurix Therapeutics shares in Q1 2026, an estimated $684K.
  • Nurix Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q1 2026, its #1860 holding.
  • Victory Capital Management first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 16 quarters since.
  • Victory Capital Management's Nurix Therapeutics position peaked at $1.13M in Q4 2024.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.